Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bionomics Ltd BNOX

Healthcare Biotechnology
Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its... see more

Recent & Breaking News (NDAQ:BNOX)

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

GlobeNewswire September 14, 2023

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

GlobeNewswire August 23, 2023

Quarterly Activities and Cashflow Report

GlobeNewswire July 31, 2023

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

GlobeNewswire July 25, 2023

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

GlobeNewswire July 3, 2023

Bionomics to Present at Upcoming June Investor Conferences

GlobeNewswire June 15, 2023

Bionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

GlobeNewswire May 30, 2023

Quarterly Activities and Cashflow Report

GlobeNewswire April 28, 2023

Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

GlobeNewswire April 27, 2023

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

GlobeNewswire March 8, 2023

Bionomics' Half-Year Report

GlobeNewswire February 23, 2023

Quarterly Activities and Cashflow Report

GlobeNewswire January 30, 2023

Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

GlobeNewswire December 18, 2022

Bionomics appoints Spyridon "Spyros" Papapetropoulos as President and Chief Executive Officer

GlobeNewswire December 15, 2022

Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

GlobeNewswire December 2, 2022

Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States

GlobeNewswire November 21, 2022

Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States

GlobeNewswire November 16, 2022

Bionomics Limited to Participate in Upcoming November Investor Conferences

GlobeNewswire November 2, 2022

Quarterly Activities Report for September 2022

GlobeNewswire October 25, 2022

Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million

GlobeNewswire October 18, 2022